Clinical Impact of PET Imaging in Patients With Metastatic Prostate Cancer.


Tuncel M., Tuncalı M., Telli T., Erman M.

Clinical nuclear medicine, vol.45, pp.757-764, 2020 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45
  • Publication Date: 2020
  • Doi Number: 10.1097/rlu.0000000000003126
  • Journal Name: Clinical nuclear medicine
  • Journal Indexes: Science Citation Index Expanded, Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.757-764
  • Keywords: F-18-FDG, Ga-68-DOTATATE, Ga-68-PSMA, Lu-177-PSMA, neuroendocrine differentiation, prostate cancer, THERAPY

Abstract

Prostate cancer (Pca) is the most common cancer and the second leading cause of death among men. Although conventional bone scans and abdominal CT are preferred in most of the guidelines and clinical trials, PET/CT has already started to become the inevitable part of Pca management because of its higher sensitivity and specificity. Radiotracers used for PET imaging show different molecular aspects of the disease process. Although(68)Ga-prostate-specific membrane antigen offers the highest sensitivity and specificity, other PET radiotracers such as(18)F-FDG and(68)Ga-DOTATATE still have a role in patients with prostate-specific membrane antigen-negative diseases such as Pca with neuroendocrine differentiation. In this pictorial essay, we have presented a series of patients with metastatic Pca who had PET images with different radiotracers and discussed the clinical role of this imaging modality in patient management.